454 related articles for article (PubMed ID: 19020753)
1. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
2. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Raje N; Hideshima T; Mukherjee S; Raab M; Vallet S; Chhetri S; Cirstea D; Pozzi S; Mitsiades C; Rooney M; Kiziltepe T; Podar K; Okawa Y; Ikeda H; Carrasco R; Richardson PG; Chauhan D; Munshi NC; Sharma S; Parikh H; Chabner B; Scadden D; Anderson KC
Leukemia; 2009 May; 23(5):961-70. PubMed ID: 19151776
[TBL] [Abstract][Full Text] [Related]
5. [Effects of lovastatin on cell cycle distribution in MCF-7 cells transfected with BRCA1].
Luo YQ; Mi MT; Wei N; Xu HX; Zhu JD
Ai Zheng; 2004 Aug; 23(8):924-8. PubMed ID: 15301716
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
[TBL] [Abstract][Full Text] [Related]
8. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
Glassford J; Rabin N; Lam EW; Yong KL
Br J Haematol; 2007 Oct; 139(2):243-54. PubMed ID: 17897300
[TBL] [Abstract][Full Text] [Related]
9. Regulating expressions of cyclin D1, pRb, and anti-cancer effects of deguelin on human Burkitt's lymphoma Daudi cells in vitro.
Liu HL; Chen Y; Cui GH; Wu QL; He J
Acta Pharmacol Sin; 2005 Jul; 26(7):873-80. PubMed ID: 15960896
[TBL] [Abstract][Full Text] [Related]
10. Berberine inhibits cyclin D1 expression via suppressed binding of AP-1 transcription factors to CCND1 AP-1 motif.
Luo Y; Hao Y; Shi TP; Deng WW; Li N
Acta Pharmacol Sin; 2008 May; 29(5):628-33. PubMed ID: 18430372
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression.
Gao QZ; Lu JJ; Liu ZD; Zhang H; Wang SM; Xu H
Asian J Androl; 2008 Jul; 10(4):635-41. PubMed ID: 18097517
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cell cycle progression by penta-acetyl geniposide in rat C6 glioma cells.
Chang YC; Chou FP; Huang HP; Hsu JD; Wang CJ
Toxicol Appl Pharmacol; 2004 Jul; 198(1):11-20. PubMed ID: 15207644
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment.
Venkataraman G; Maududi T; Ozpuyan F; Bahar HI; Izban KF; Qin JZ; Alkan S
Leuk Res; 2006 Nov; 30(11):1377-84. PubMed ID: 16624404
[TBL] [Abstract][Full Text] [Related]
14. [Effect of deguelin on proliferation and apoptosis of lymphoma Daudi cells and its mechanism].
Liu HL; Chen Y; Cui GH; Wu QL; Chen WH; He J
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):176-80. PubMed ID: 17649631
[TBL] [Abstract][Full Text] [Related]
15. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
16. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.
Ju JF; Banerjee D; Lenz HJ; Danenberg KD; Schmittgen TC; Spears CP; Schönthal AH; Manno DJ; Hochhauser D; Bertino JR; Danenberg PV
Clin Cancer Res; 1998 May; 4(5):1315-22. PubMed ID: 9607592
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells.
Ahn MY; Lee J; Na YJ; Choi WS; Lee BM; Kang KW; Kim HS
Chem Biol Interact; 2009 May; 179(2-3):169-77. PubMed ID: 19070610
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
[TBL] [Abstract][Full Text] [Related]
19. Estrogen accelerates G1 to S phase transition and induces a G2/M phase-predominant apoptosis in synthetic vascular smooth muscle cells.
Yang Z; Cheng B; Song J; Wan Y; Wang Q; Cheng B; Chen X
Int J Cardiol; 2007 Jun; 118(3):381-8. PubMed ID: 17055086
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
